CRDF

$0.86+2.23%visit website

Cardiff Oncology, Inc.

Market Cap

$67M

Live price × SEC shares (Aug 6, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.50

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

132.2

TTM to Jun 2026 · revenue

P/B

2.5

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	120	243	41	104	508
Research & development	8,197	5,075	6,765	5,915	25,952
Selling, general & administrative	3,897	2,995	6,126	3,804	16,822
Total operating expenses	12,094	8,070	12,891	9,719	42,774
Operating income	(11,974)	(7,827)	(12,850)	(9,615)	(42,266)
Net income	(11,258)	(7,216)	(12,345)	(9,232)	(40,051)
EPS (basic) ($)	(0.17)		(0.18)	(0.14)	(0.60)
EPS (diluted) ($)	(0.17)		(0.18)	(0.14)	(0.60)
Weighted avg. shares (basic)	66,879		68,350	68,397
Weighted avg. shares (diluted)	66,879		68,350	68,397

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 11, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 58 more quarters, back to Mar 2011, with Tormere Pro.

Corporate Events (8-K)

16 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Oct 27, 2026 accepted 4:44 PM ET	5.02Officer / director change5.03Bylaws / fiscal year7.01Reg FD disclosure	Document SEC ↗
Oct 22, 2026 accepted 4:30 PM ET	5.07Shareholder vote	Document SEC ↗
Sep 14, 2026 accepted 9:28 AM ET	1.01Material agreement7.01Reg FD disclosure	Document SEC ↗
Aug 11, 2026 accepted 4:11 PM ET	2.02Earnings release	Document SEC ↗
Jul 16, 2026 accepted 8:38 AM ET	1.01Material agreement8.01Other events	Document SEC ↗
Jun 11, 2026 accepted 4:15 PM ET	5.07Shareholder vote	Document SEC ↗
Jun 3, 2026 accepted 8:30 AM ET	7.01Reg FD disclosure	Document SEC ↗
May 29, 2026 accepted 5:11 PM ET	1.01Material agreement	Document SEC ↗
May 19, 2026 accepted 5:01 PM ET	8.01Other events	Document SEC ↗
May 14, 2026 accepted 4:15 PM ET	2.02Earnings release	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

42%

W/W -30.4pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-07-14	2026-07-16	PACE GARY W	Director	Purchase	687.3K	$1.46	$1000K	2.04M	View
2026-07-14	2026-07-16	Mohindru Mani	Director & Chief Executive Officer	Purchase	34.4K	$1.46	$50K	59.1K	View
2026-06-18	2026-06-22	Mohindru Mani	Director & Chief Executive Officer	Purchase	24.7K	$1.21	$30K	24.7K	View
2026-06-18	2026-06-22	PACE GARY W	Director	Purchase	30.0K	$1.22	$37K	1.36M	View
2025-07-30	2025-07-31	PACE GARY W	Director	Purchase	290.0K	$2.45	$711K	1.35M	View

Recent News

Cardiff Oncology to Participate in the UBS Global Biopharma Conference

Yahoo · 2026-11-03

Cardiff Oncology (CRDF) Slips 2.41% to $0.89 as Traders Watch $0.85 Support - Daily Profile

https://www.dars.gov.et/ · 2026-10-31

Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer

Yahoo · 2026-10-27

All trial patients still enrolled have had over 18 months of treatment. Cardiff Oncology names an interim medical chief.

Stock Titan · 2026-10-27

Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia

Yahoo · 2026-10-21

Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement

Yahoo Finance · 2026-09-14

Cardiff Oncology to Participate in September 2026 Conferences

Yahoo Finance · 2026-09-02

$CRDF stock is up 14% today. Here's what we see in our data.

Quiver Quantitative · 2026-08-24

CRDF: Second Quarter Earnings

Yahoo Finance · 2026-08-17

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Yahoo Finance · 2026-08-11

Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital

Yahoo Finance · 2026-07-15

Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?

Yahoo Finance · 2026-06-30

CRDF Forecast — Price Target — Prediction for 2027

TradingView · 2026-06-25

Cardiff Oncology: Market Dismisses Onvansertib's Potential In First-Line Colorectal Cancer

Seeking Alpha · 2026-04-06

symbol__ Stock Quote Price and Forecast

CNN · 2024-01-11

Informational purposes only, not investment advice.

Date	Insider	Type	Shares	Value
2026-07-14	PACE GARY W	P	687,285	$999,999.68
2026-07-14	Mohindru Mani	P	34,364	$49,999.62
2026-06-18	Mohindru Mani	P	24,703	$29,890.63
2026-06-18	PACE GARY W	P	30,000	$36,600
2025-07-30	PACE GARY W	P	275,000	$673,750

CRDF

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

Cardiff Oncology, Inc. (CRDF)

Reporting Insiders

Factor Profile

Corporate Events (8-K)